Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAUNA: SSA Continuation in GEP-NET
NCT05701241Phase 4Recruiting
- Start
- Jun 2023
- Primary completion
- Apr 2029
- Modality
- Peptides
- Countries
- 2
01
Overview
A Phase 4 trial of octreotide, lanreotide in gastroenteropancreatic neuroendocrine tumor (GEP-NET). Started Jun 2023; status: recruiting.
02
Drugs
octreotidelanreotide
03
Conditions
gastroenteropancreatic neuroendocrine tumor (GEP-NET)
Beyond the preview
Go deeper on NCT05701241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05701241.